A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
← catalyst calendarNCT06892522 · readout ≤ 3,421 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
602estimated
Sites
34
Countries
Australia, Israel, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | Dec 2035 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Etentamig
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Daratumumab
- Drug: Dexamethasone
- Drug: Carfilzomib
- Drug: Mezigdomide
- Drug: Iberdomide
- Drug: ABBV-2001
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AE)s
measured Up to Approximately 130 Months
Substudy 1: Dose-Limiting Toxicity (DLT) of Etentamig + Daratumumab and Lenalidomide (DR) in Participants with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)
measured Up to Approximately 8 weeks
Substudy 2: DLT of Etentamig Monotherapy as Maintenance in Participants with Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM)
measured Up to Approximately 8 Weeks
Substudy 3: DLT of Etentamig +Carfilzomib and Dexamethasone (Kd) Combination in Participants with Relapsed or Refractory Multiple Myeloma (RR MM)
measured Up to Approximately 8 Weeks
Substudy 4: DLT of Etentamig plus Lenalidomide when Given as Maintenance in Participants with TE NDMM
measured Up to Approximately 8 Weeks
Substudy 5: DLT of ABBV-2001 in Combination with Iberdomide in Participants with RR MM
measured Up to Approximately 8 Weeks
Substudy 6: DLT of ABBV-2001 in Combination with Mezigdomide in Participants with RR MM
measured Up to Approximately 8 Weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed